Auteur: Wilbert Bannenberg

  • Amsterdam UMC resumes supply of compounded CDCA

    Amsterdam UMC resumes supply of compounded CDCA The Pharmaceutical Accountability Foundation welcomes the news that the Amsterdam UMC (Amsterdam University Medical Centers) has resumed supplying Dutch patients with the rare disease Cerebrotendinous Xanthomathosis (CTX) with pharmacy compounded chenodeoxycholic acid (CDCA).[1] This action became necessary after Leadiant Biosciences had increased the price of one CDCA capsule […]

    READ MORE